Tanaka S, Kanomata N, Teramura K, Wakita K, Kunihisa T, Yano Y, Moriya T, Hayashi Y
Division of Infectious Disease Pathology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Department of Pathology, Yodogawa Christian Hospital, Osaka, Osaka, Japan.
Cytopathology. 2016 Dec;27(6):465-471. doi: 10.1111/cyt.12335. Epub 2016 Apr 6.
The Breast Marker Cocktail from Biocare Medical comprises five antibodies recognising p63, and cytokeratins (CKs) 7, 18, 5 and 14. Immunohistochemistry using this cocktail is useful for diagnosing proliferative intraductal breast lesions. However, cytology using the cocktail has not been reported.
We report 139 cases of mammary samples collected by fine needle aspiration (FNA) for which histological diagnoses were available. After cell transfer, immunocytochemistry was performed using the cocktail, and clusters of cells were classified. A cluster with no or limited CK5/14 expression (<20% of cells) was classified as a monotonous cluster. One with more than 20% of cells showing CK5/14 expression was defined as a mosaic cluster. When at least one p63-positive cell was present, we defined it as a cluster with p63. We also evaluated background p63-positive myoepithelial cell densities.
The diagnostic sensitivity and specificity for carcinomas were 97.8% (89/91) and 91.7% (11/12), respectively, using the criterion of two or more monotonous clusters lacking p63. Two false-negative cases were triple-negative cancers; one false-positive was an apocrine papilloma. The numbers of monotonous clusters with p63 differed significantly between benign lesions, ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS) and invasive carcinomas (P < 0.001). The background myoepithelial cell density was significantly higher in fibroepithelial tumours than in other lesions (P < 0.001).
Immunocytochemistry using this antibody cocktail showed good sensitivity and specificity for diagnosing breast cancers. Thus, this method is useful for mammary cytology using FNA.
Biocare Medical公司生产的乳腺标志物组合试剂包含五种抗体,可识别p63以及细胞角蛋白(CK)7、18、5和14。使用该组合试剂进行免疫组织化学有助于诊断乳腺导管内增生性病变。然而,尚未有关于使用该组合试剂进行细胞学检查的报道。
我们报告了139例通过细针穿刺抽吸(FNA)采集的乳腺样本,这些样本均有组织学诊断结果。细胞转移后,使用该组合试剂进行免疫细胞化学检测,并对细胞簇进行分类。CK5/14表达缺失或有限(<20%的细胞)的细胞簇被分类为单调细胞簇。CK5/14表达细胞超过20%的细胞簇被定义为镶嵌细胞簇。当至少有一个p63阳性细胞时,我们将其定义为含有p63的细胞簇。我们还评估了背景p63阳性肌上皮细胞密度。
以两个或更多缺乏p63的单调细胞簇为标准,对癌的诊断敏感性和特异性分别为97.8%(89/91)和91.7%(11/12)。两例假阴性病例为三阴性癌;一例假阳性为大汗腺乳头状瘤。良性病变、导管原位癌(DCIS)/小叶原位癌(LCIS)和浸润性癌之间,含有p63的单调细胞簇数量差异有统计学意义(P < 0.001)。纤维上皮性肿瘤的背景肌上皮细胞密度显著高于其他病变(P < 0.001)。
使用该抗体组合试剂进行免疫细胞化学检测对乳腺癌诊断具有良好的敏感性和特异性。因此,该方法对FNA乳腺细胞学检查有用。